- Home
- TMCWW vs OSRHW Comparison
TMCWW vs OSRHW Comparison
Compare TMCWW & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMCWW | OSRHW |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Canada | United States |
| Employees | 48 | 22 |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | TMCWW | OSRHW |
|---|---|---|
| Price | $0.25 | $0.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 149.5K | 26.8K |
| Earning Date | 03-24-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.03 |
| 52 Week High | $3.84 | $0.10 |
Technical Indicators
Market Signals| Indicator | TMCWW | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 48.28 |
| Support Level | $0.24 | $0.04 |
| Resistance Level | $0.50 | $0.06 |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 31.58 | 0.00 |
Price Performance
Historical ComparisonAbout TMCWW TMC the metals company Inc.
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.